A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

Exclusion Criteria

• •Known sensitivity to DMEM/F-12 or any component of the study material.
• •Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
• •Subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
• •A history of drug or alcohol abuse within 1 year of study enrollment.
• •Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
• •Any clinically significant abnormal laboratory parameters.
• •A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
• •Dermatologic condition in donation and/or study areas.
• •Prior surgery in the treatment area.
• •Insufficient hair or scarring in the donor area that might impact cell growth.
• •Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.